956821-91-3

Basic information

• Product Name: 2-Methyl-6-nitro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline
• Synonyms: 2-Methyl-6-nitro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline
• CAS NO: 956821-91-3
• Molecular Formula: C₁₃H₁₉BN₂O₄
• Molecular Weight: 278.11196
• Mol File: 956821-91-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Methyl-6-nitro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-6-nitro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline(956821-91-3)
• EPA Substance Registry System: 2-Methyl-6-nitro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline(956821-91-3)

Safety Data

• Hazardous Substances Data: 956821-91-3(Hazardous Substances Data)

Upstream product

• 77811-44-0 4-bromo-2-methyl-6-nitroaniline 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1054315-49-9 tert-butyl 4-(4-amino-3-methyl-5-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 1228013-63-5 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine 

Relevant articles and documents

MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY

Provided herein are Heteroaryl Compounds having the following structure: R2 N (I) or (II) wherein R1 -R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3- (6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl) pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kin

We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity. This lead compound was found to have potent CYP3A4 inhibition, CYP3A4 induction mediated by PX

HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES

A compound of formula I, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or solvate thereof, methods of using such compounds in the treatment of hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases; and to pharmaceutical compositions containing such compounds